EGFR and malignant colon neoplasm: To mention, the Pt-Dd structure could be further improved for delivery purposes by specific targeting to different cellular receptors through modification of cell-recognition domains in the fiber [57] or the addition of monoclonal antibodies to target overexpressed receptors in tumors, such as herceptin or erbitux to target Her2/neu or EGFR in breast and colon cancer, respectively.